In recent years multipotent haematopoietic stem cell (HSC) therapy has become a popular technique with a range of promising health benefits. A broad variety of possibilities makes this cutting-edge therapy a turning point in modern medicine. One of the recognized challenges is the ability to quickly obtain a sufficient number of desired cell types for transplantation, with high purity. Today, the time-consuming sample preparation steps and the considerable loss of cells during the process are still significant challenge. The MARS platform addresses it through an easy method to isolate CD34+ cells from mobilized blood.
